Correlation Between Endoscopic Findings And Helicobacter Pylori Infection

Status Recruiting

Clinical Trial Summary

The aim of this study is to 1. Evaluate frequency of H. pylori infection in patients with CKD. 2. Description the gastroduodenal lesions found in patients with chronic kidney disease and correlate it to H.pylori infection.

Clinical Trial Description

cross sectional study to study the relationship between Helicobacter Pylori Infection and Gastroduodenal Lesions in Patients with Chronic Kidney Disease, There have been some debates about the association of Helicobacter pylori infection and chronic kidney disease (CKD). Pathogenesis of H. pylori infection in patients with CKD is not clearly revealed and there are not enough studies about these two factors. There are several hypothesis which support that kidney disease may reduce H. pylori infection. High level of serum urea nitrogen can contribute to a decreased gastric acid secretion and higher gastric alkalosis which could be the cause of lower prevalence of H. pylori among CKD. Inflammatory cytokines are also increased in CKD patients and it can cause gastric mucosal damage, chronic gastritis, and spontaneously eradicate H. pylori. In addition, antibiotics, proton pump inhibitors, or H2 receptor antagonists which are used in patients with CKD for long time might be associated with decreased H. pylori infection. There are other hypothesis that are contrary to above theories. Some studies showed that high u rea concentration makes the gastric mucosa more susceptible to H. pylori and infection rate is higher in uremic patients. And, in some articles which have studied about peptic ulcer in CKD, the prevalence of H. pylori infection looked lower compare to ulcer in non-CKD patients but real incidence may not be lower. Because the incidence of peptic ulcer is higher in CKD patients with various causes except H. pylori infection. Gastrointestinal (GI) disorders are the most prevalent chronic problem in CKD patients, ranking second in frequency only to renal failure itself. GI disorders affect 70 to 80% of patients on Hemodialysis (HD); yet, little is known about the impact of Hp infection on this multifactorial disorder. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05927766
Study type	Interventional
Source	Sohag University
Contact	mohamed f ebdalla, dr
Phone	01062271010
Email	mohamedfaisel@med.sohag.edu.eg
Status	Recruiting
Phase	N/A
Start date	July 1, 2023
Completion date	December 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06386172` - Electronic Decision-support System to Improve Detection and Care of Patients With Chronic Kidney Disease in Stockholm	N/A
Recruiting	`NCT04910867` - APOL1 Genetic Testing Program for Living Donors	N/A
Completed	`NCT03434145` - Changes of Ocular Structures After Hemodialysis in Patients With Chronic Kidney Diseases	N/A
Recruiting	`NCT04984226` - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD	Phase 2
Active, not recruiting	`NCT05887817` - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)	Phase 4
Recruiting	`NCT05318196` - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
Terminated	`NCT05022329` - COVID-19 Vaccine Boosters in Patients With CKD	Phase 2/Phase 3
Not yet recruiting	`NCT04925661` - HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia	Phase 1
Recruiting	`NCT04961164` - Resistant Starch Prebiotic Effects in Chronic Kidney Disease	N/A
Completed	`NCT05015647` - Low Protein Diet in CKD Patients at Risk of Malnutrition	N/A
Completed	`NCT03426787` - Helping Empower Liver and Kidney Patients	N/A
Recruiting	`NCT06094231` - Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study	N/A
Completed	`NCT04363554` - The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease	N/A
Recruiting	`NCT04831021` - Pre- or Per-dialytic Physical Exercise : a Cardioprotective Role?	N/A
Terminated	`NCT04877847` - Multi-Center Trial Utilizing Low Frequency Ultrasound in the Prevention of Post-Contrast Acute Kidney Injury	N/A
Recruiting	`NCT04422652` - Combination of Novel Therapies for CKD Comorbid Depression	Phase 2
Completed	`NCT05055362` - Effect a Honey, Spice-blended Baked Good Has on Salivary Inflammation Markers in Adults: a Pilot Study	N/A
Not yet recruiting	`NCT06330480` - Check@Home: General Population Screening for Early Detection of Atrial Fibrillation and Chronic Kidney Disease	N/A
Recruiting	`NCT03176862` - Left Ventricular Fibrosis in Chronic Kidney Disease	N/A
Terminated	`NCT02539680` - Intestinal Phosphate Transporter Expression in CKD Patients	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Correlation Between Endoscopic Findings And Helicobacter Pylori Infection In Chronic Kidney Disease Patients

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms